Wedbush Comments on Kiniksa Pharmaceuticals Ltd’s Q1 2020 Earnings (NASDAQ:KNSA)

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) – Analysts at Wedbush issued their Q1 2020 earnings per share estimates for shares of Kiniksa Pharmaceuticals in a note issued to investors on Tuesday, August 13th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of ($0.82) per share for the quarter. Wedbush has a “Buy” rating on the stock. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2020 earnings at ($0.91) EPS, Q3 2020 earnings at ($0.92) EPS and Q4 2020 earnings at ($0.95) EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03.

Several other research analysts have also commented on the company. ValuEngine raised Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research raised Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Friday. Finally, JMP Securities cut their target price on Kiniksa Pharmaceuticals to $35.00 and set a “market outperform” rating for the company in a research note on Wednesday. They noted that the move was a valuation call. Five analysts have rated the stock with a buy rating, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and an average target price of $26.50.

Shares of NASDAQ KNSA opened at $9.41 on Wednesday. Kiniksa Pharmaceuticals has a 12 month low of $9.08 and a 12 month high of $32.88. The firm has a market capitalization of $514.74 million, a price-to-earnings ratio of -2.70 and a beta of -1.56. The business has a 50-day moving average of $12.92 and a 200-day moving average of $15.48.

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA boosted its stake in shares of Kiniksa Pharmaceuticals by 1,131.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,685 shares of the company’s stock valued at $48,000 after purchasing an additional 2,467 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Kiniksa Pharmaceuticals by 33.1% during the second quarter. JPMorgan Chase & Co. now owns 3,832 shares of the company’s stock valued at $52,000 after purchasing an additional 952 shares during the period. D. E. Shaw & Co. Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $268,000. M&T Bank Corp purchased a new stake in shares of Kiniksa Pharmaceuticals during the second quarter valued at approximately $141,000. Finally, Bank of America Corp DE boosted its stake in shares of Kiniksa Pharmaceuticals by 1,021.6% during the fourth quarter. Bank of America Corp DE now owns 11,631 shares of the company’s stock valued at $327,000 after purchasing an additional 10,594 shares during the period. 29.79% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Featured Story: Asset Allocation Models, Which is Right For You?

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.